These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 20307796)

  • 1. From research to the real world: buprenorphine in the decade of the Clinical Trials Network.
    Ling W; Jacobs P; Hillhouse M; Hasson A; Thomas C; Freese T; Sparenborg S; McCarty D; Weiss R; Saxon A; Cohen A; Straus M; Brigham G; Liu D; McLaughlin P; Tai B
    J Subst Abuse Treat; 2010 Jun; 38 Suppl 1(Suppl 1):S53-60. PubMed ID: 20307796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.
    Amass L; Ling W; Freese TE; Reiber C; Annon JJ; Cohen AJ; McCarty D; Reid MS; Brown LS; Clark C; Ziedonis DM; Krejci J; Stine S; Winhusen T; Brigham G; Babcock D; Muir JA; Buchan BJ; Horton T
    Am J Addict; 2004; 13 Suppl 1(Suppl 1):S42-66. PubMed ID: 15204675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review.
    Yokell MA; Zaller ND; Green TC; Rich JD
    Curr Drug Abuse Rev; 2011 Mar; 4(1):28-41. PubMed ID: 21466501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study.
    Chakrabarti A; Woody GE; Griffin ML; Subramaniam G; Weiss RD
    Drug Alcohol Depend; 2010 Mar; 107(2-3):253-6. PubMed ID: 19948382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
    Mammen K; Bell J
    Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.
    Orman JS; Keating GM
    Drugs; 2009; 69(5):577-607. PubMed ID: 19368419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.
    Strain EC; Stoller K; Walsh SL; Bigelow GE
    Psychopharmacology (Berl); 2000 Mar; 148(4):374-83. PubMed ID: 10928310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine in the treatment of opiate dependence: its pharmacology and social context of use in the U.S.
    Wesson DR
    J Psychoactive Drugs; 2004 May; Suppl 2():119-28. PubMed ID: 15279124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
    Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
    Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine and naloxone for heroin dependence.
    Johnson RE; McCagh JC
    Curr Psychiatry Rep; 2000 Dec; 2(6):519-26. PubMed ID: 11123005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs approved for opiate dependence.
    FDA Consum; 2003; 37(1):6. PubMed ID: 12625293
    [No Abstract]   [Full Text] [Related]  

  • 12. Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.
    Mooney LJ; Nielsen S; Saxon A; Hillhouse M; Thomas C; Hasson A; Stablein D; McCormack J; Lindblad R; Ling W
    Contemp Clin Trials; 2013 Mar; 34(2):196-204. PubMed ID: 23159524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine.
    Harris DS; Jones RT; Welm S; Upton RA; Lin E; Mendelson J
    Drug Alcohol Depend; 2000 Dec; 61(1):85-94. PubMed ID: 11064186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accessing opiate dependence treatment medications: buprenorphine products in an office-based setting.
    Leshner AI
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S103-4. PubMed ID: 12738354
    [No Abstract]   [Full Text] [Related]  

  • 16. Buprenorphine maintenance: a new treatment for opioid dependence.
    Collins GB; McAllister MS
    Cleve Clin J Med; 2007 Jul; 74(7):514-20. PubMed ID: 17682629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients: does it serve as a bridge to hepatitis C virus therapy?
    Taylor LE; Maynard MA; Friedmann PD; Macleod CJ; Rich JD; Flanigan TP; Sylvestre DL
    J Addict Med; 2012 Sep; 6(3):179-85. PubMed ID: 22614935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid dependence treatment, including buprenorphine/naloxone.
    Raisch DW; Fye CL; Boardman KD; Sather MR
    Ann Pharmacother; 2002 Feb; 36(2):312-21. PubMed ID: 11847954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Narrative review: buprenorphine for opioid-dependent patients in office practice.
    Sullivan LE; Fiellin DA
    Ann Intern Med; 2008 May; 148(9):662-70. PubMed ID: 18458279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine/Naloxone (Zubsolv
    Heo YA; Scott LJ
    CNS Drugs; 2018 Sep; 32(9):875-882. PubMed ID: 30117074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.